Abstract |
Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.
|
Authors | J Jawień, M Gajda, R Olszanecki, R Korbut |
Journal | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
(J Physiol Pharmacol)
Vol. 58
Issue 3
Pg. 583-8
(Sep 2007)
ISSN: 0867-5910 [Print] Poland |
PMID | 17928652
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Apolipoproteins E
- Azo Compounds
- Lipoxygenase Inhibitors
- Quinolines
- Receptors, LDL
- 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid
- oil red O
|
Topics |
- Animals
- Aorta
(drug effects, metabolism, pathology)
- Apolipoproteins E
(genetics, metabolism)
- Atherosclerosis
(drug therapy, genetics, metabolism)
- Azo Compounds
(chemistry)
- Female
- Lipoxygenase Inhibitors
(chemistry, pharmacology, therapeutic use)
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Molecular Structure
- Quinolines
(chemistry, pharmacology, therapeutic use)
- Receptors, LDL
(genetics, metabolism)
- Staining and Labeling
(methods)
|